Product news from the 10/31/06 News Brief

Share this article:
The FDA has approved Novartis’ Tyzeka (telbivudine) for patients with chronic hepatitis B. Alpharma won FDA approval for its 80 mg dosage strength of chronic pain treatment Kadian (morphine sulfate). The company expects to launch this new dosage strength during the fourth-quarter of 2006. Kadian is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.